CA3171906A1 - Novel antigen binding domains and synthetic antigen receptors incorporating the same - Google Patents

Novel antigen binding domains and synthetic antigen receptors incorporating the same

Info

Publication number
CA3171906A1
CA3171906A1 CA3171906A CA3171906A CA3171906A1 CA 3171906 A1 CA3171906 A1 CA 3171906A1 CA 3171906 A CA3171906 A CA 3171906A CA 3171906 A CA3171906 A CA 3171906A CA 3171906 A1 CA3171906 A1 CA 3171906A1
Authority
CA
Canada
Prior art keywords
antigen
cell
sar
receptor
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3171906A
Other languages
English (en)
French (fr)
Inventor
Preet M. Chaudhary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of CA3171906A1 publication Critical patent/CA3171906A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3171906A 2020-03-16 2021-03-16 Novel antigen binding domains and synthetic antigen receptors incorporating the same Pending CA3171906A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990396P 2020-03-16 2020-03-16
US62/990,396 2020-03-16
PCT/US2021/022641 WO2021188599A1 (en) 2020-03-16 2021-03-16 Novel antigen binding domains and synthetic antigen receptors incorporating the same

Publications (1)

Publication Number Publication Date
CA3171906A1 true CA3171906A1 (en) 2021-09-23

Family

ID=77768273

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3171906A Pending CA3171906A1 (en) 2020-03-16 2021-03-16 Novel antigen binding domains and synthetic antigen receptors incorporating the same

Country Status (12)

Country Link
US (1) US20230212319A1 (https=)
EP (2) EP4592310A2 (https=)
JP (1) JP2023518049A (https=)
KR (1) KR20220169488A (https=)
CN (1) CN116194130A (https=)
AU (1) AU2021237570A1 (https=)
BR (1) BR112022018359A2 (https=)
CA (1) CA3171906A1 (https=)
IL (1) IL296411A (https=)
MX (1) MX2022011417A (https=)
WO (1) WO2021188599A1 (https=)
ZA (1) ZA202210400B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3240805T3 (fi) 2014-12-15 2025-02-17 Univ California Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN113272319A (zh) * 2018-12-27 2021-08-17 国立大学法人京都大学 T细胞受体的变体
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
CN115776991A (zh) * 2020-05-07 2023-03-10 华夏英泰（北京）生物技术有限公司 改进的t细胞受体-共刺激分子嵌合物
US20230203125A1 (en) * 2020-05-22 2023-06-29 Chongqing Precision Biotech Co., Ltd. Fusion protein for reversing tumor microenvironment and use thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN113880953A (zh) * 2020-07-01 2022-01-04 华夏英泰（北京）生物技术有限公司 T细胞抗原受体、其多聚体复合物及其制备方法和应用
US20220089642A1 (en) * 2020-09-17 2022-03-24 City Of Hope Fc Receptor-ACE2 Conjugates and Use Thereof
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
WO2023086379A2 (en) * 2021-11-10 2023-05-19 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3239740A1 (en) * 2021-12-03 2023-06-08 Tim C. LEUTKENS High selective cd229 antigen binding domains and methods of use
AU2022423987A1 (en) * 2021-12-29 2024-07-11 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
CN118871460A (zh) * 2022-01-07 2024-10-29 维硕公司 经工程化的PD-L1靶向γδT细胞受体
CA3245762A1 (en) * 2022-03-25 2023-09-28 Shanghai Henlius Biologics Co., Ltd. ANTI-MSLN ANTIBODIES AND METHODS OF USE
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN115786272B (zh) * 2023-01-05 2025-02-14 厦门大学 靶向SARS-Cov-2的TCR-T的制备方法及其应用
WO2024148337A1 (en) * 2023-01-05 2024-07-11 Angeles Therapeutics, Inc. Methods and compositions for gene transduction and to control the activity of synthetic and immune receptors
WO2024189620A1 (en) * 2023-03-13 2024-09-19 Canopy Immuno-Therapeutics Ltd. Ig-like fusion proteins for treating pemphigus vulgaris and foliaceus
KR20250131823A (ko) 2023-03-31 2025-09-03 아벨제타 인크. Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
EP4694900A1 (en) * 2023-04-13 2026-02-18 The Johns Hopkins University Engineered t-cell receptors and methods of making and using the same
CN117143823B (zh) * 2023-09-11 2024-07-16 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用
WO2025213182A1 (en) * 2024-04-05 2025-10-09 The Board Of Trustees Of The Leland Stanford Junior University Combinatorial approaches for targeting hematopoietic cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
US20260015401A1 (en) * 2024-07-10 2026-01-15 Angeles Therapeutics, Inc. Compositions and methods comprising epitopes and polypeptides

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
PT2768942T (pt) 2011-10-17 2020-01-21 Massachusetts Inst Technology Entrega intracelular
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
WO2015069922A2 (en) * 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
BR112016018100A2 (pt) 2014-02-07 2018-02-20 Univ Mcmaster acoplador antigênico de células t trifuncional, métodos e usos do mesmo
EP3209699A1 (en) 2014-10-22 2017-08-30 Crescendo Biologics Limited Vh scaffold
DK3209698T4 (da) 2014-10-22 2022-04-04 Crescendo Biologics Ltd Transgene mus
GB201500463D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
GB201500464D0 (en) 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
BR112017013981A2 (pt) 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
DE102015101304B3 (de) 2015-01-29 2016-03-17 Fujitsu Technology Solutions Intellectual Property Gmbh Rackserver für ein Serverrack
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
WO2016168769A1 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Chimeric receptor t cell switches for her2
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
KR20180075689A (ko) 2015-11-23 2018-07-04 트르스티스 오브 보스톤 유니버시티 키메라 항원 수용체에 관한 방법 및 조성물
GB201607968D0 (en) 2016-05-06 2016-06-22 Crescendo Biolog Ltd Chimeric antigen receptor
IL322083A (en) 2016-08-24 2025-09-01 Teneobio Inc Non-human transgenic animals that produce modified heavy chain antibodies only
EP3529268B1 (en) 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
JP7291396B2 (ja) * 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
EP3548055A4 (en) * 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
US20190359678A1 (en) * 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
CN106939048A (zh) * 2017-03-25 2017-07-11 康众（北京）生物科技有限公司 一种CD3ε×CD19双特异性纳米抗体及其制备方法
JP7538601B2 (ja) * 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
KR20250007003A (ko) 2017-06-20 2025-01-13 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
ES2928296T3 (es) 2017-06-30 2022-11-16 Us Health Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos
EP3681908A1 (en) 2017-09-13 2020-07-22 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
WO2019067805A1 (en) 2017-09-27 2019-04-04 University Of Southern California NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY
KR20250070609A (ko) 2017-11-14 2025-05-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
CN111683966B (zh) 2017-12-22 2023-07-11 特尼奥生物股份有限公司 与cd22结合的重链抗体
EP3746470A1 (en) 2018-01-31 2020-12-09 F. Hoffmann-La Roche AG Stabilized immunoglobulin domains
JOP20200234A1 (ar) 2018-03-27 2020-09-15 Xyphos Biosciences Inc نطاقات a1-a2 معدلة لمركبات ترابطية nkg2d غير طبيعية ترتبط بمستقبلات nkg2d غير طبيعية.
JP7599205B2 (ja) 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
CN112566643A (zh) * 2018-06-12 2021-03-26 加利福尼亚大学董事会 用于治疗癌症的单链双特异性嵌合抗原受体
BR112020024074A2 (pt) * 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
JP7641223B2 (ja) 2019-01-28 2025-03-06 サイフォス、バイオサイエンシズ、インコーポレイテッド Ｃａｒ細胞上の非天然ｎｋｇ２ｄ受容体に、結合した異種分子を選択的に送達する改変非天然ｎｋｇ２ｄリガンド

Also Published As

Publication number Publication date
EP4121079A4 (en) 2024-10-30
JP2023518049A (ja) 2023-04-27
BR112022018359A2 (pt) 2023-01-24
KR20220169488A (ko) 2022-12-27
WO2021188599A1 (en) 2021-09-23
AU2021237570A1 (en) 2022-09-08
CN116194130A (zh) 2023-05-30
US20230212319A1 (en) 2023-07-06
IL296411A (en) 2022-11-01
EP4592310A2 (en) 2025-07-30
EP4121079A1 (en) 2023-01-25
MX2022011417A (es) 2023-01-04
ZA202210400B (en) 2025-04-30

Similar Documents

Publication Publication Date Title
CA3171906A1 (en) Novel antigen binding domains and synthetic antigen receptors incorporating the same
US20240390496A1 (en) Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
JP7685735B2 (ja) 合成免疫受容体およびその使用方法
CN113286879B (zh) 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子
JP2023145589A (ja) 共刺激のための新規のプラットフォーム、新規のｃａｒ設計、および養子細胞療法のための他の増強
EP2850106B1 (en) Bispecific scfv immunofusion (bif) binding to cd123 and cd3
CA3056374A1 (en) Anti-psma antibodies and use thereof
US12590133B2 (en) IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof
JP2024523316A (ja) Ｃａｒ ｔ細胞における、および疾患の処置のための抗ｃｄ３０７ｅ単一ドメイン抗体、その使用
CN117202921A (zh) 用于多种免疫细胞的单链和多链合成抗原受体
HK40127002A (en) Novel antigen binding domains and synthetic antigen receptors incorporating the same
JP2026513651A (ja) Ａｄｇｒｅ２キメラ受容体ｎｋ細胞組成物及び使用方法
BR122025006733A2 (pt) Usos de células expressando receptor de antígeno quimérico (car) e de um adaptador
RU2822461C1 (ru) Трансгенные генетические метки и способы применения
HK40026612A (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
EA052459B1 (ru) Синтетические иммунные рецепторы и способы их применения

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250307

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250307

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250307

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250312

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250313

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250318

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250318

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250318

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20260107

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260107